Medtronic’s final separation from MiniMed has created another odd-lot situation worth watching.
Medtronic plc (NYSE: MDT) is offering shareholders the chance to exchange MDT shares for shares of MiniMed Group, Inc. (Nasdaq: MMED). The offer is designed to deliver approximately $107.53 of MiniMed stock for each $100 of Medtronic stock accepted, subject to a maximum exchange ratio of 4.5939 MMED shares for each MDT share.
There is also an odd-lot provision: beneficial holders of fewer than 100 Medtronic shares who validly tender all of their shares are not subject to proration if the exchange offer is oversubscribed.
That makes 99 MDT shares the obvious paper-trade size to examine.
How the Medtronic-MiniMed Exchange Offer Works
MiniMed was Medtronic’s diabetes business before becoming a separately traded company earlier this year. Medtronic completed the MiniMed IPO in March 2026 but retained approximately 90% of the company afterward.
The current exchange offer is the step intended to complete that separation. Medtronic is offering up to 225,361,295 MiniMed shares in exchange for MDT shares and may dispose of additional MiniMed shares if the offer is oversubscribed.
This completes a process that began well before MiniMed reached the public markets. StockSpinoffs covered Medtronic’s original MiniMed separation plan in August 2025, when the company was still describing a structure built around an IPO followed by a split-off.
The IPO has happened. The split-off is now here.
The Headline Discount Is About 7.53%
The exchange offer is structured around a 7% discount to the relative trading values of MDT and MMED.
If the upper limit does not apply, an investor whose MDT shares are accepted should receive approximately $107.53 of MiniMed stock for each $100 of Medtronic stock tendered. That works out to a gross value uplift of about 7.53% relative to the MDT value surrendered.
The final exchange ratio will be determined using the arithmetic average of the daily volume-weighted average prices of MDT and MMED during the three-day valuation period expected to be October 5, 6 and 7, assuming the offer is not extended.
The offer is scheduled to expire at midnight New York City time at the end of October 9.
The 4.5939-Share Cap Matters
The headline 7.53% gross spread is not guaranteed.
Medtronic will not issue more than 4.5939 MiniMed shares for each Medtronic share accepted in the offer. If the price relationship between MDT and MMED would otherwise require a higher exchange ratio, the cap applies and the effective discount shrinks.
Using the September 23 closing prices of approximately $89.30 for MDT and $20.54 for MMED as a simple reference point, an uncapped 7% discount would imply an exchange ratio of roughly 4.67 MMED shares per MDT share.
That is above the 4.5939-share cap.
At those same reference prices, 4.5939 MMED shares would be worth about $94.36 for each MDT share tendered. Compared with $89.30 of MDT surrendered, that is a gross spread of roughly 5.7%.
Those are not the final economics because the actual exchange ratio depends on the October valuation-period VWAPs. But they show why this offer requires more attention than simply seeing “7% discount” and assuming the full spread is locked in.
Why 99 Shares Are Different
If the exchange offer is oversubscribed, Medtronic can prorate tenders.
That means an investor who tenders a larger position might have only part of it accepted. The unaccepted MDT shares would remain in the account, leaving the investor with continued Medtronic exposure and less of the exchange-offer spread than expected.
The odd-lot rule creates an exception.
According to the exchange-offer prospectus, beneficial holders of fewer than 100 MDT shares who properly tender all of their shares are exempt from proration.
Someone who owns 99 MDT shares and tenders all 99 therefore has a structurally different position from someone who owns 100 shares or more.
As with every odd-lot tender, the details matter. An investor who owns fewer than 100 shares but tenders only part of the position does not qualify for the odd-lot preference.
Our 99-Share Paper Trade
Using MDT’s September 23 closing price of approximately $89.30 as the reference point, a hypothetical 99-share position would cost:
99 × $89.30 = $8,840.70
If the full 7.53% gross value uplift were available, the implied MiniMed value received would be roughly $9,506 before fees, taxes and market movement.
But if the 4.5939 upper limit were binding at the September 23 MMED price of about $20.54, the implied MiniMed value would instead be approximately:
99 × 4.5939 × $20.54 = $9,341.51
That would represent a gross gain of about $500.81, or approximately 5.7%, before transaction costs, taxes and changes in either stock price.
This is why I would track the paper trade from the entry price while also watching whether the upper limit remains in effect as the valuation period approaches.
The Odd-Lot Advantage Could Matter If the Offer Is Popular
Medtronic shareholders are being offered MiniMed shares at a discount, so oversubscription is entirely possible.
If that happens, ordinary tenders can be prorated. A qualifying 99-share odd-lot tender avoids that problem, assuming the shares are properly tendered and all conditions are satisfied.
The value of the odd-lot provision therefore depends partly on demand for the offer. If there is little enough participation that everyone is accepted, the exemption adds no practical benefit. If the offer is heavily oversubscribed, avoiding proration can materially improve the trade.
That is the same dynamic we just saw in the Computer Modelling Group tender, where the odd-lot preference became valuable precisely because ordinary tenders were expected to be prorated.
This Is a Split-Off, Not a Normal Spinoff
Medtronic shareholders are not automatically receiving MiniMed shares.
Participation is voluntary. An MDT shareholder can exchange some or all eligible shares for MMED, subject to the offer terms, or simply keep the Medtronic shares.
That is a split-off structure rather than a conventional pro rata spinoff. Existing shareholders make an active choice about whether they want to continue holding Medtronic or exchange some of that exposure for MiniMed.
The exchange offer is expected to be generally tax-free for U.S. federal income tax purposes for participating shareholders, but individual tax circumstances can differ and the prospectus contains substantial tax discussion that investors should review.
What Could Go Wrong?
The most obvious risk is price movement.
The exchange ratio is calculated from the relative VWAPs of MDT and MMED during the valuation period. MiniMed can fall after the ratio is set and before the investor is able to sell the received shares. Medtronic can also move, changing the economics relative to the original purchase price.
The upper limit is another important risk. If it applies, the investor receives less than the headline $107.53 of MMED for each $100 of MDT tendered.
There are also operational risks. Brokers can impose earlier tender deadlines than the official expiration date, corporate-action fees can reduce the return, and an incorrectly submitted odd-lot tender can lose the proration exemption.
Finally, this is a substantially larger trade than some of the sub-$500 odd-lot tenders we have tracked. Buying 99 MDT shares at current prices requires nearly $9,000 of capital, so even a favorable percentage spread comes with meaningfully greater dollar exposure to price movements.
What I’m Watching Before October 9
The most important number is the indicative exchange ratio.
Medtronic’s information agent is publishing indicative calculations during the offer period, and the final ratio is expected immediately before expiration. The key question is whether the 4.5939-share upper limit remains in effect when the valuation period arrives.
I also want to see whether the offer appears likely to be oversubscribed. That determines how much practical value the odd-lot exemption ultimately provides.
For the paper portfolio, the setup is straightforward: 99 MDT shares at a $89.30 reference price, tender all 99, track the final exchange ratio, and calculate the value of the MMED shares ultimately received.
After the offer closes, I’ll come back and compare the actual outcome with the paper trade—just as we did with the CMG tender.